source
- Kyverna reports positive one-year CAR-T results for rare stiff person syndrome, supporting FDA filingKyverna Therapeutics announced that its CAR-T therapy for stiff person syndrome showed positive results after one year of treatment. The trial involved patients with the rare autoimmune disorder,…
- Novartis and Novo Nordisk trials lower biomarkers but fail to cut heart events, prompting preventive cardiology rethinkThe article discusses two recent Phase 3 trials that achieved their biological goals but did not improve clinical outcomes. Novartis reported that pelacarsen in the Lp(a) HORIZON study successfull…STAT · 1mo agoNegative readoutNegative